New Krill Oil Concentrate, Probiotics for Womens, Oral Health at Vitafoods Europe

Aker BioMarine and Bifodan launched new supplement products at Vitafoods Europe in Geneva, Switzerland, May 10-12, including a krill oil concentrate from Aker BioMarine and probiotic solutions for women’s health and oral health from Bifodan.

Using newly acquired technology called Flexitech™, Aker BioMarine launched its first krill oil concentrate, Superba™ Boost Caps. Superba Boost Caps contain higher amounts of phospholipids and omega-3s compared to the previous generation of Superba Krill Oil, and also qualify for four EU-authorized health claims (based on a dosage of two capsules), including:

Further, Superba received Novel Foods Approval at extended use levels in April, allowing a dose of more than 250 mg EPA/DHA (up to 3,000 mg) per day in the EU. Superba Boost Caps also offer a higher concentration of key actives—phospholipids, omega-3s EPA/DHA and choline—and improved smell and taste. 

Bifodan A/S introduced two proprietary probiotic solutions backed by clinical research: Oral Extra and FemiOral Balance.  

Oral Extra is a unique combination of two proprietary lactobacilli strains, which have been studied in a clinical trial at the University of Copenhagen. The study was aimed at determining its effect on oral health parameters specific to gingivitis, a condition affecting 50 to 90 percent of the adult population worldwide. The results were significant, in favor of Oral Extra, which is offered in a cool, lemon-flavored lozenge.

“In a double-blind, placebo-controlled study recently completed, the reduction in gingival crevicular fluid was significant in the group treated with Oral Extra, compared to the placebo group," Mette Kirstine Keller, principal investigator and assistant professor, said, adding, “Gingival crevicular fluid is an important marker for inflammation of the gums."  

FemiOral Balance is based on a patented combination of two proprietary strains. The effect of this unique combination on vaginal health has been studied extensively and the level of evidence allows for a medical device certification of an orally administered capsule.

The company is presenting both products as Vitafoods Europe in Geneva, Switzerland, May 10-12.